Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Samuel Aballéa

Showing results (1-10 of 74) with videos related to

Pageof 8
Sort By:
Health Economics|December 14, 2006
Seeing for yourself: feasibility study towards valuing visual impairment using simulation spectaclesSamuel Aballéa, Aki Tsuchiya
Journal of Market Access & Health Policy|June 4, 2019
Measuring the health-related quality of life in young children: how far have we come?Nicola Germain, Samuel Aballéa, Mondher Toumi
Public Health|September 5, 2021
The real-life impact of vaccination on COVID-19 mortality in Europe and IsraelKatarzyna Jabłońska, Samuel Aballéa, Mondher Toumi
Public Health|April 23, 2021
Factors influencing the COVID-19 daily deaths' peak across European countriesKatarzyna Jabłońska, Samuel Aballéa, Mondher Toumi
Journal of Market Access & Health Policy|March 27, 2026
Can We Trust PAICs in Rare Diseases? Methodological Challenges and LimitationsMikolaj Parkitny, Samuel Aballéa, Piotr Wojciechowski, et al.
Journal of Market Access & Health Policy|November 18, 2021
On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in EuropeKatarzyna Jabłońska, Samuel Aballéa, Pascal Auquier, et al.
Psychiatry Research|December 3, 2015
Association between social contact frequency and negative symptoms, psychosocial functioning and quality of life in patients with schizophreniaKarin Siegrist, Aurelie Millier, Ikbal Amri, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 26, 2016
About the advantages and disadvantages of discrete-event simulation for health economic analysesMondher Toumi, Ekkehard Beck, Steve Sherman, et al.
Journal of Market Access & Health Policy|September 7, 2019
Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness resultsJunwen Zhou, Aurélie Millier, Clément François, et al.
Journal of Market Access & Health Policy|April 25, 2025
Clinical Trial Validity Guidance from the HTACG: Looking for Chicken TeethMondher Toumi, Bruno Falissard, Asma Jouini, et al.
Pageof 8

Showing results (1-10 of 74) with videos related to

Sort By:
Pageof 8
Health Economics|December 14, 2006
Seeing for yourself: feasibility study towards valuing visual impairment using simulation spectaclesSamuel Aballéa, Aki Tsuchiya
Journal of Market Access & Health Policy|June 4, 2019
Measuring the health-related quality of life in young children: how far have we come?Nicola Germain, Samuel Aballéa, Mondher Toumi
Public Health|September 5, 2021
The real-life impact of vaccination on COVID-19 mortality in Europe and IsraelKatarzyna Jabłońska, Samuel Aballéa, Mondher Toumi
Public Health|April 23, 2021
Factors influencing the COVID-19 daily deaths' peak across European countriesKatarzyna Jabłońska, Samuel Aballéa, Mondher Toumi
Journal of Market Access & Health Policy|March 27, 2026
Can We Trust PAICs in Rare Diseases? Methodological Challenges and LimitationsMikolaj Parkitny, Samuel Aballéa, Piotr Wojciechowski, et al.
Journal of Market Access & Health Policy|November 18, 2021
On the association between SARS-COV-2 variants and COVID-19 mortality during the second wave of the pandemic in EuropeKatarzyna Jabłońska, Samuel Aballéa, Pascal Auquier, et al.
Psychiatry Research|December 3, 2015
Association between social contact frequency and negative symptoms, psychosocial functioning and quality of life in patients with schizophreniaKarin Siegrist, Aurelie Millier, Ikbal Amri, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|November 26, 2016
About the advantages and disadvantages of discrete-event simulation for health economic analysesMondher Toumi, Ekkehard Beck, Steve Sherman, et al.
Journal of Market Access & Health Policy|September 7, 2019
Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness resultsJunwen Zhou, Aurélie Millier, Clément François, et al.
Journal of Market Access & Health Policy|April 25, 2025
Clinical Trial Validity Guidance from the HTACG: Looking for Chicken TeethMondher Toumi, Bruno Falissard, Asma Jouini, et al.
Pageof 8